Latest News
Connecting ADME and Mouse Models in Preclinical Oncology
In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...
Latest News
Rakuten Medical Appoints Former Takeda CEO Christophe Weber to Board
Rakuten Medical Appoints Christophe Weber as Vice Chairman and Ken Takeshita, M.D., as Director to Accelerate US Growth and Oncology Innovation Enhanced Board and leadership team, including the appointment of a new Chief Medical Officer, strengthens governance,...
Why Hormone Health Knowledge Could Improve Female Staff Retention
The life sciences sector is built on evidence, innovation and better health outcomes. So why is women’s hormone health at work still so often treated as a peripheral issue, asks Sarah Davies, Managing Director of Balance@Work? Life sciences organisations spend their...
Tozorakimab COPD Trial Data Reach Below the Eosinophil Gate
AstraZeneca released the full tozorakimab COPD trial results on 8 September 2026. The company presented them as a late breaker at the European Respiratory Society Congress in Barcelona. The slot was the ALERT-2 plenary session. The New England Journal of Medicine...
Section 232 Pharma Tariffs: What Changes on 29 September
On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Natural Diamonds in Healthcare
When we say "diamonds," most people think of a luxurious necklace or a super sparkly ring. A research lab would be the last place people imagine them being used. Interestingly, natural diamonds are getting a lot of attention in science and healthcare research. And...
Clinical Trials Roundup | 03 April 2026
Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...
Erectile Dysfunction is Preventable – if You Act Early
Did you know that your erections can tell you more about your heart health than you might think? Nocturnal erections—those spontaneous erections that happen during sleep—are directly tied to vascular health. When a man stops having them, even for a short period of...
Rethinking Lifestyle Diseases: From Risk Factors to Root Causes
Are we mistaking associations for true biological origins? Despite significant advances in modern medicine, lifestyle diseases such as cardiovascular disease and diabetes continue to rise globally. These conditions are commonly described as “multifactorial,”...
Rethinking Commercial Strategy for Late Biopharma Entrants
Being first to market in a new therapeutic class is often seen as a winning formula in biopharma. In reality, many of the biggest commercial successes come second, or even later. The difference is not luck. It is timing, differentiation and scale. Understanding late...
Python Blood Molecule Opens Door to New Obesity Treatments
Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...
Weekly News Roundup | 30 March 2026
Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...
International Menopause Society Unveils Global Care Framework
International Menopause Society sets new global standards for menopause care with evidence-led framework For the first time in a decade, the International Menopause Society (IMS) has released a complete redevelopment of its global menopause recommendations. Grounded...
Clinical Trials Roundup | 27 March 2026
An RNA therapy that preserves muscle while cutting visceral fat, a first in class oral non incretin obesity pill, late stage lung cancer portfolio data, NK cell immunotherapy in Alzheimer’s disease, and the first human trial of a cellular rejuvenation medicine...
New Report Highlights Why CGTs Still Struggle at Market Access
Cell and gene therapies are approved — so why aren’t they reaching patients? New industry report warns access systems — not science — are now the primary bottleneck A new report from Phacilitate argues that the biggest threat to cell and gene therapy (CGT) expansion...
The Radical Longevity Science Frontier
For decades, longevity has been a frontier of scientific exploration, pushing the boundaries of what we believe is possible for human health and lifespan. While incremental progress has been made in understanding the biology of aging, we are now on the cusp of a new...
Key Thoughts from the on! PLUS TPL Review
The evolving PMTA landscape for nicotine pouches The recent FDA authorisation of on! PLUS nicotine pouches is a significant moment in helping meet tobacco harm reduction (THR) goals. They are the first products to pass a new, faster FDA programme, signifying a...
Natural Diamonds in Healthcare
When we say "diamonds," most people think of a luxurious necklace or a super sparkly ring. A research lab would be the last place people imagine them being used. Interestingly, natural diamonds are getting a lot of attention in science and healthcare research. And...
Clinical Trials Roundup | 03 April 2026
Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...
Erectile Dysfunction is Preventable – if You Act Early
Did you know that your erections can tell you more about your heart health than you might think? Nocturnal erections—those spontaneous erections that happen during sleep—are directly tied to vascular health. When a man stops having them, even for a short period of...
Rethinking Lifestyle Diseases: From Risk Factors to Root Causes
Are we mistaking associations for true biological origins? Despite significant advances in modern medicine, lifestyle diseases such as cardiovascular disease and diabetes continue to rise globally. These conditions are commonly described as “multifactorial,”...
Rethinking Commercial Strategy for Late Biopharma Entrants
Being first to market in a new therapeutic class is often seen as a winning formula in biopharma. In reality, many of the biggest commercial successes come second, or even later. The difference is not luck. It is timing, differentiation and scale. Understanding late...
Python Blood Molecule Opens Door to New Obesity Treatments
Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...
Weekly News Roundup | 30 March 2026
Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...
International Menopause Society Unveils Global Care Framework
International Menopause Society sets new global standards for menopause care with evidence-led framework For the first time in a decade, the International Menopause Society (IMS) has released a complete redevelopment of its global menopause recommendations. Grounded...
Clinical Trials Roundup | 27 March 2026
An RNA therapy that preserves muscle while cutting visceral fat, a first in class oral non incretin obesity pill, late stage lung cancer portfolio data, NK cell immunotherapy in Alzheimer’s disease, and the first human trial of a cellular rejuvenation medicine...
New Report Highlights Why CGTs Still Struggle at Market Access
Cell and gene therapies are approved — so why aren’t they reaching patients? New industry report warns access systems — not science — are now the primary bottleneck A new report from Phacilitate argues that the biggest threat to cell and gene therapy (CGT) expansion...
The Radical Longevity Science Frontier
For decades, longevity has been a frontier of scientific exploration, pushing the boundaries of what we believe is possible for human health and lifespan. While incremental progress has been made in understanding the biology of aging, we are now on the cusp of a new...
Key Thoughts from the on! PLUS TPL Review
The evolving PMTA landscape for nicotine pouches The recent FDA authorisation of on! PLUS nicotine pouches is a significant moment in helping meet tobacco harm reduction (THR) goals. They are the first products to pass a new, faster FDA programme, signifying a...
Featured Articles
Further News
How to Move Faster Without Losing Scientific Rigor or Compliance
Life science organizations are under pressure to do two things at once: communicate complex science with precision and keep pace with a digital market that moves in days, not quarters. This tension defines one of the most consequential challenges in modern life...
Agentic AI is Having a Moment: The Foundations go Back 40 Years
The application of agentic AI in life sciences reached a tipping point in 2025. Frameworks where specialized agents collaborate on tasks, sharing work, dividing problems, communicating with each other, went from an emerging topic to the predominant conversation. For...
From Flower to Pharmacy: The Science Behind Manuka Honey
Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...
Weekly News Roundup | 23 March 2026
Your essential life science news 23 March 2026 digest: the past week’s biggest stories in pharma, biotech and healthcare. The FDA approved Johnson and Johnson's once-daily psoriasis pill ICOTYDE (icotrokinra) on 18 March, making it the world's first oral peptide to...
Clinical Trials Roundup
This week brought a remarkable series of clinical trial readouts spanning oncology, metabolic disease, neurology, and dermatology. Several pivotal datasets were released from late-stage and early-stage programmes, offering fresh hope for patients with conditions...
Power Outages as a Clinical Risk Multiplier in Healthcare
Electricity as a Hidden Dependency in Healthcare Reliable electricity is a foundational requirement for modern healthcare systems. From acute hospital care to long-term residential facilities and home-based treatment, uninterrupted power underpins virtually every...
I’m a Menopause Doctor – Here’s the Real Problem with Fezolinetant
With news of a HRT alternative for women struggling with hot flushes now available on the NHS, Dr Louise Newson explains why when it comes to Fezolinetant, women need to proceed with caution. UK medicines regulator NICE reported that they're in the final stages of...
The Physician Gap That’s Slowing Life Sciences
We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further...
Bridging the Gap Between Microbiome Research and Patient Care
Advances in microbiome science are occurring faster than our ability to apply these insights within complex human systems. While research has dramatically expanded what can be observed within the gut, translating these discoveries into meaningful improvements in...
Protecting R&D and Clinical Trial Data in the Age of AI
Drug development is one of the most expensive and time-intensive innovation processes in the world. Estimates from the Tufts Center for the Study of Drug Development suggest that bringing a new drug to market can cost over $2.6 billion and take more than a decade of...
Medical Writers Become Strategic Partners
In regulated drug development, documentation shapes how a program is understood long before regulators ever see it. Protocols, investigator brochures, integrated summaries, and submission-ready modules establish the scientific and strategic narrative of a development...
HIV Treatment Revolution: Infected Cells Now Trigger Their Own Elimination
Imagine a virus so cunning it hides in your body's own cells, evading detection for decades while you take daily pills just to keep it at bay. That's the reality for nearly 40 million people living with HIV worldwide. But what if we could flip the script—turning those...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.